Abstract
Chromatographic separation serves as “a workhorse” for downstream process development and plays a key role in the removal of product-related, host-cell-related, and process-related impurities. Complex and poorly characterized raw materials and feed material, low feed concentration, product instability, and poor mechanistic understanding of the processes are some of the critical challenges that are faced during the development of a chromatographic step. Traditional process development is performed as a trial-and-error-based evaluation and often leads to a suboptimal process. A high-throughput process development (HTPD) platform involves the integration of miniaturization, automation, and parallelization and provides a systematic approach for time- and resource-efficient chromatographic process development. Creation of such platforms requires the integration of mechanistic knowledge of the process with various statistical tools for data analysis. The relevance of such a platform is high in view of the constraints with respect to time and resources that the biopharma industry faces today.
This protocol describes the steps involved in performing the HTPD of chromatography steps. It describes the operation of a commercially available device (PreDictor™ plates from GE Healthcare). This device is available in 96-well format with 2 or 6 μL well size. We also discuss the challenges that one faces when performing such experiments as well as possible solutions to alleviate them. Besides describing the operation of the device, the protocol also presents an approach for statistical analysis of the data that are gathered from such a platform. A case study involving the use of the protocol for examining ion exchange chromatography of the Granulocyte Colony Stimulating Factor (GCSF), a therapeutic product, is briefly discussed. This is intended to demonstrate the usefulness of this protocol in generating data that are representative of the data obtained at the traditional lab scale. The agreement in the data is indeed very significant (regression coefficient 0.93). We think that this protocol will be of significant value to those involved in performing the high-throughput process development of the chromatography process.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Bhambure R, Kumar K, Rathore AS (2011) High-throughput process development for biopharmaceutical drug substances. Trends Biotechnol 29:127–135
Allen L (2017) The evolution of platform technologies for the downstream processing of antibodies. In: Gottschalk U (ed) Process scale purification of antibodies. John Wiley & Sons Inc., Hoboken, NJ, p 365
Rathore AS, Kumar D, Kateja N (2018) Recent developments in chromatographic purification of biopharmaceuticals. Biotechnol Lett 40:1–11
Rathore AS, Singh SK (2016) Production of protein therapeutics in the quality by design (QbD) paradigm. In: Sauna ZE, Kimchi-Sarfaty C (eds) Protein therapeutics. Springer, Cham, p 41
Rathore AS (2016) Quality by design (QbD)-based process development for purification of a biotherapeutic. Trends Biotechnol 34:358–370
Petroff MG, Bao H, Welsh JP et al (2016) High throughput chromatography strategies for potential use in the formal process characterization of a monoclonal antibody. Biotechnol Bioeng 113:1273–1283
Wiendahl M, Wierling PS, Nielsen J et al (2008) High throughput screening for the design and optimization of chromatographic processes – miniaturization, automation and parallelization of breakthrough and elution studies. Chem Eng Technol 31:893–903
Wierling PS, Bogumil R, Knieps-Grunhagen E et al (2007) High-throughput screening of packed-bed chromatography coupled with SELDI-TOF MS analysis: monoclonal antibodies versus host cell protein. Biotechnol Bioeng 98:440–450
Susanto A, Treier K, Knieps-Grunhagen E et al (2009) High throughput screening for the design and optimization of chromatographic processes: automated optimization of chromatographic phase systems. Chem Eng Technol 32:140–154
Bergander T, Nilsson-Valimaa K, Oberg K et al (2008) High-throughput process development: determination of dynamic binding capacity using microtiter filter plates filled with chromatography resin. Biotechnol Prog 24:632–639
Kramarczyk JF, Kelley BD, Coffman JL (2008) High-throughput screening of chromatographic separations: II. Hydrophobic interaction. Biotechnol Bioeng 100:702–720
Kelley BD, Switzer M, Bastek P et al (2008) High-throughput screening of chromatographic separations: IV. Ion-exchange. Biotechnol Bioeng 100:950–963
Bailey MJ, Hooker AD, Adams CS et al (2005) A platform for high-throughput molecular characterization of recombinant monoclonal antibodies. J Chromatogr B 826:177–187
Nfor BK, Noverraz M, Chilamkurthi S et al (2010) High-throughput isotherm determination and thermodynamic modeling of protein adsorption on mixed mode adsorbents. J Chromatogr B 1217:6829–6850
Chhatre S, Bracewell DG, Titchener-Hooker NJ (2009) A microscale approach for predicting the performance of chromatography columns used to recover therapeutic polyclonal antibodies. J Chromatogr A 1216:7806–7815
Titchener-Hooker NJ, Dunnill P, Hoare M (2008) Micro biochemical engineering to accelerate the design of industrial–scale downstream processes for biopharmaceutical proteins. Biotechnol Bioeng 100:473–487
Bhambure R, Rathore AS (2013) Chromatography process development in the QbD paradigm I. Establishing a high throughput process development (HTPD) platform as a tool for establishing “characterization space” for an ion exchange chromatography step. Biotechnol Prog 29:403–414
Diederich P, Hoffmann M, Hubbuch J (2015) High-throughput process development of purification alternatives for the protein avidin. Biotechnol Prog 31:957–973
Rathore AS, Winkle H (2009) Quality by design for biopharmaceuticals: regulatory perspective and approach. Nat Biotechnol 27:26–34
Rathore AS (2009) A roadmap for implementation of quality by design (QbD) for biotechnology products. Trends Biotechnol 27:546–553
Read EK, Park JT, Shah RB et al (2010) Process analytical technology (PAT) for biopharmaceutical products: concepts and applications – part I. Biotechnol Bioeng 105:276–284
Read EK, Park JT, Shah RB et al (2010) Process analytical technology (PAT) for biopharmaceutical products: concepts and applications – part II. Biotechnol Bioeng 105:285–295
Rathore AS, Bhambure R, Ghare V (2010) Process analytical technology (PAT) for biopharmaceutical products. Anal Bioanal Chem 398:137–154
Rathore AS, Ghare V, Bhambure R (2011) Process analytical technology (PAT) for bioseparation unit operations. In: Undey C, Low D, De Menezes JMC (eds) Process analytical technology applied in biopharmaceutical process development and manufacturing. Taylor and Francis, Boca Raton, FL, pp 179–200
Roch P, Mandenius CF (2016) On-line monitoring of downstream bioprocesses. Curr Opin Chem Eng 14:112–120
Patel BA, Pinto ND, Gospodarek A et al (2017) On-line ion exchange liquid chromatography as a process analytical technology for monoclonal antibody characterization in continuous bioprocessing. Anal Chem 89:11357–11365
Joshi VS, Kumar V, Rathore AS (2017) Optimization of ion exchange sigmoidal gradients using hybrid models: implementation of quality by design in analytical method development. J Chromatogr A 1491:145–152
Kumar V, Bhalla A, Rathore AS (2014) Design of experiments applications in bioprocessing: concepts and approach. Biotechnol Prog 30:86–99
Rathore AS, Pathak M, Godara A (2016) Process development in the QbD paradigm: role of process integration in process optimization for production of biotherapeutics. Biotechnol Prog 32:355–362
Shekhawat LK, Godara A, Kumar V, Rathore AS (2018) Design of experiments applications in bioprocessing: chromatography process development using split DOE. Biotechnol Prog. https://doi.org/10.1002/btpr.2730
Tustian AD, Laurin L, Ihre H et al (2018) Development of a novel affinity chromatography resin for platform purification of bispecific antibodies with modified protein a binding avidity. Biotechnol Prog. https://doi.org/10.1002/btpr.2622
Rodriguez-Aller M, Guillarme D, Beck A, Fekete S (2016) Practical method development for the separation of monoclonal antibodies and antibody-drug-conjugate species in hydrophobic interaction chromatography, part 1: optimization of the mobile phase. J Pharm Biomed Anal 118:393–403
Gagnon P, CheungCW LEJ et al (2010) Minibodies and multimodal chromatography methods. BioProcess Int 8:26–35
Joshi VS, Kumar V, Rathore AS (2015) Role of organic modifier and gradient shape in RP-HPLC separation: analysis of GCSF variants. J Chromatogr Sci 53:417–423
Rathore AS, Sharma C, Malhotra D (2012) Computational fluid dynamics (CFD) as a tool for establishing design space for mixing in a bioreactor. Biotechnol Prog 28:382–391
Harms J, Wang X, Kim T et al (2008) Defining design space for biotech products: case study of Pichia pastoris fermentation. Biotechnol Prog 24:655–662
Acknowledgments
Financial assistance from the Department of Biotechnology, Government of India, New Delhi, is gratefully acknowledged. We are also thankful to GE Healthcare (Uppsala, Sweden) for providing us with financial support and some of the consumable items used in this investigation. We also thank Dionex Corporation, USA, for donating some of the equipment for this project.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Rathore, A.S., Bhambure, R. (2021). High-Throughput Process Development: I—Process Chromatography. In: Labrou, N.E. (eds) Protein Downstream Processing. Methods in Molecular Biology, vol 2178. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-0775-6_2
Download citation
DOI: https://doi.org/10.1007/978-1-0716-0775-6_2
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-0774-9
Online ISBN: 978-1-0716-0775-6
eBook Packages: Springer Protocols